3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
34
Lung Neoplasms
11
Brain Neoplasms
2
Radiation Pneumonitis
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
1
NSCLC
1
Meningeal Carcinomatosis
1
Liver Diseases
1
Digestive System Diseases
1
Carcinoma
1
Aumolertinib
1
Advanced Non-small Cell Lung Cancer
1
Adenocarcinoma
1
Interventions
Carboplatin
12
Pemetrexed
11
pembrolizumab
10
Paclitaxel
6
Cisplatin
6
Erlotinib Hydrochloride
5
Docetaxel
5
Nivolumab
4
Gefitinib
4
spartalizumab
3
osimertinib
3
Gemcitabine
3
EC145
3
Crizotinib
3
Afatinib
3
technetium 99m etarfolatide
2
pralsetinib
2
fludarabine
2
cemiplimab
2
brigatinib
2
alpha-2'-deoxythioguanosine
2
aldesleukin
2
Vinorelbine
2
Radiotherapy
2
Quality of Life
2
MORAb-202
2
Immunotherapy
2
Drug Therapy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
aumolertinib
×
Thoracic
×
Clear all
NCT04401059
2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4
Unknown
744 enrolled